The life sciences intelligence API
Every paper. Every trial.
Every drug. Every approval.
One API.
39M+ publications, 575K+ clinical trials, 22K+ molecules, and the full FDA & EMA regulatory record, down to the drug labels, review documents, and EPARs. All cross-linked in one API.
BiomedCorePublicationsTrialCoreClinical trialsDrugCoreMoleculesRegulatoryCoreFDA + EMA
Find work by the two scientists most central to GLP-1 biology: Lotte Bjerre Knudsen (Novo Nordisk, designed semaglutide) and Daniel Drucker (Toronto, discovered GLP-1's incretin effect).
Request
GET https://api.amass.tech/api/v1/cores/biomedcore/records?query=GLP-1%20receptor%20agonist%20obesity&include=authorsMetadata&minPublicationDate=2018-01-01&authorNames=Lotte%20Bjerre%20Knudsen&authorNames=Daniel%20Drucker
query=GLP-1 receptor agonist obesityinclude=authorsMetadataminPublicationDate=2018-01-01authorNames=Lotte Bjerre Knudsen, Daniel Drucker
Response · 200 OK
{ "data": [ { "amassId": "AMBC_RwzeOtqYiRA2S523v1jL81OgndQ", "pmid": "34626851", "pmcid": "PMC8859548", "doi": "10.1016/j.molmet.2021.101351", "title": "GLP-1 physiology informs the pharmacotherapy of obesity", "abstract": "BACKGROUND: Glucagon-like peptide-1 receptor agonists (GLP1RA) augment glucose-dependent insulin release and reduce glucagon secretion and gastric emptying, enabling their successful development for the treatment of type 2 diabetes (T2D).…", "authors": ["Daniel J. Drucker"], "journal": "Molecular metabolism", "issn": "2212-8778", "volumeIssue": "57", "language": "eng", "publicationDate": "2022-03-01", "publicationTypes": ["Journal Article", "Research Support, Non-U.S. Gov't", "Review"], "isRetracted": false, "citationCount": 423, "journalQualityJufo": 2, "meshTerms": ["Adolescent", "Animals", "Diabetes Mellitus, Type 2", "Glucagon-Like Peptide 1", "Glucagon-Like Peptide-1 Receptor", …], "keywords": ["Brain", "Diabetes", "G protein-coupled receptor", "Hunger", "Obesity", …], "substances": ["Glucagon-Like Peptide-1 Receptor", "Liraglutide", "Glucagon-Like Peptide 1"], "hasFulltext": false, "authorsMetadata": [ { "name": "Daniel J. Drucker", "orcid": "0000-0001-6688-8127", "affiliations": [{ "name": "Lunenfeld-Tanenbaum Research Institute", "ror": "01s5axj25", "countryCode": "CA" }] } ], "meshIds": ["D000293", "D000818", "D003924", "D052216", "D000067757", …], "substanceIds": ["D000067757", "D000069450", "D052216"], "referencesTrialCore": [], "references": ["AMBC_5km7Q541cJN5a8RcTUN2tcgYoRj", "AMBC_WUubCFjk6wfURImFXwtDEvKquIE", "AMBC_3pwzL1urfguQm7s2L8Jlj04onOR", "AMBC_YDNDzsaB3vLPfxW6MNxdJU7vwI0", "AMBC_KH7wBl2Araj9gbLXuQWOHefvkIs", …], "citedBy": ["AMBC_B5CfpHBkdFha6MX0Q2GJpCBMw3o", "AMBC_UAflDqTKZtUAEny8XTtIvPvCWu7", "AMBC_P2sn7qrFvXfd8grl0s5scQ2El3t", "AMBC_5Er4ez0MRO1LsHzGpqflcUlzSFZ", "AMBC_PB5LfnIhIOOXiZLcXAokubVODU8", …] }, { "pmid": "32987188", "title": "Glucagon-like peptide-1 receptor co-agonists for treating metabolic disease", "citationCount": 270, … }, { "pmid": "35907261", "title": "Glucagon-like Peptide-1 Receptor-based Therapeutics for Metabolic Liver Disease", "citationCount": 113, … }, { "pmid": "41654015", "title": "Ectopic, hepatic GLP-1R agonism enhances the weight loss efficacy of GLP-1 analogues", "citationCount": 0, … }, { "pmid": "29317623", "title": "GLP-1 release and vagal afferent activation mediate the beneficial metabolic and chronotherapeutic effects of D-allulose", "citationCount": 181, … } ] }
39M+
Publications
575K+
Clinical trials
22K+
Molecules
7K+
FDA + EMA authorizations
Cross-linked by design. Follow any paper to its trials, any molecule to its approvals, any approval back to the evidence.
Build with the Amass *Cores
Get started
From API key to first response in minutes. Auth, requests, and parsing your first result.
Built for AI agents
A one-page reference your LLM can read top to bottom — drop it into a prompt and call the API.
Example workflows
End-to-end queries for literature review, pipeline tracking, and trial intelligence.